BoardD

A Leading Institution for Knowledge Sharing and Technology Exchange in Asia

뉴스

International MOU Inked Between Chemistry and Biomedical Talents from Hong Kong, Singapore and Europe

관리자 2022.05.24 13:59

INTERNATIONAL MOU INKED BETWEEN CHEMISTRY AND BIOMEDICAL TALENTS FROM HONG KONG, SINGAPORE AND EUROPE FOR LATE-STAGE CANCER RESEARCH ENHANCEMENT




Laboratory for Synthetic Chemistry and Chemical Biology Limited (“LSCCB”), Hong Kong, Singapore life science companies Invitrocue (HK) (“IVQHK”) and European leader in lung cancer research, Dr. Rafael Rosell jointly announced their agreement to enter into a Memorandum of Understanding (“MOU”), forging international collaborations between local talents and worldwide institutes via connection to corporates’ global network.

The partnership program including two Science Park based companies LSCCB, one of the research centres under the Health@InnoHK cluster funded by Innovation and Technology Commission, while IVQHK is Hong Kong Science and Technology Parks Corporation’s park company.

The 5-year strategic partnership will study the preclinical efficacy of proprietary anticancer compounds developed by Prof. Chi-Ming Che, Lead Principal Investigator and Managing Director of LSCCB using IVQ’s breakthrough technologies, including, Onco-PDO (Patient-Derived Organoids Chemotherapeutic Test), Invivocue’s Humanized Mice Technologies, & Next Generation Sequencing (NGS). The research conducted will set forth the pathway in attempt to make advanced cancer a treatable chronic disease and improve patients’ lives.

Dr. Rafael Rosell, a renowned lung cancer expert based in Spain, will serve as clinical and scientific advisor of the project, collaborating on the study of molecular mechanisms of the anticancer compounds and advising on future clinical trial.

Along with the multilateral research framework, Invitrocue committed to offer contribution for eligible cancer patients to perform Onco-PDO Chemosensitivity Test, an in vitro drug screening on patient-specific organoid as therapeutic tool in personalized treatment, leading to more durable responses with fewer side effects from less responsive treatment. The contribution covers cancer types including lung cancer, breast cancer, nasopharyngeal cancer, pancreatic cancer, and cervical cancer.




Please click HERE to read more!